Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement:
纳特拉公司（纳斯达克：NTRA）是全球电芯DNA和基因检测领域的领导者，今天发表了以下声明：
In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant's Reveal test. Today, a jury issued a decision in Guardant's favor. We disagree with this decision and will ask the Court to overturn it.
2021年，Natera和guardant health针对彼此提起虚假广告诉讼，涉及两家公司三年前关于Guardant的Reveal测试所做的声明。今天，陪审团做出了支持Guardant的决定。我们对这个决定持不同意见，并将要求法院撤销该决定。
The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test. This case had nothing to do with the validity or utility of Signatera, and certain key pieces of evidence supporting Natera's case were not included in this trial.
陪审团被要求评估2021年短暂时间内播出的与Guardant的Reveal测试性能有关的比较广告。此案与Signatera的有效性或实用性无关，并且支持Natera案件的某些关键证据并未纳入此次审判。
In the years that have passed since these events, Signatera has become the most widely used MRD test in the U.S., extensively validated with published evidence in more than 100 peer-reviewed papers across multiple cancer types and indications.
自这些事件发生以来的几年时间里，Signatera已成为美国最广泛使用的MRD测试，经过丰富的验证，并在100多篇同行评议文献中以多种癌症类型和适应症进行了发表。